Cyclin-Dependent Kinase 4/6 Inhibitors Plus Endocrine Therapy versus Endocrine Therapy Alone for HR-Positive, HER-2-Negative Early Breast Cancer: Meta-Analysis of Phase III Randomized Clinical Trials.
Francisco Cezar Aquino de MoraesGustavo de Oliveira AlmeidaVinícius Freire Costa AlvesJonathan N PrianttiGiovanna da Conceição GomesSarah Vitória Bristot CarnevalliThiago MadeiraMaysa VilbertCarlos SteccaMaria Cristina Figueroa MagalhãesMarianne Rodrigues FernandesNey Pereira Carneiro Dos SantosPublished in: Journal of personalized medicine (2024)
Our results show that the addition of CDK4/6 inhibitors is associated with a significant benefit for HR+/HER2- esBC patients in iDFS. More studies and longer follow-up are needed to assess overall survival benefits.
Keyphrases
- phase iii
- end stage renal disease
- early breast cancer
- cell cycle
- clinical trial
- ejection fraction
- newly diagnosed
- open label
- chronic kidney disease
- peritoneal dialysis
- prognostic factors
- patient reported outcomes
- phase ii
- signaling pathway
- bone marrow
- cell death
- free survival
- case control
- pi k akt
- study protocol
- patient reported
- chemotherapy induced